F. Barba et al. / Tetrahedron Letters 54 (2013) 1835–1838
1837
CH2
H
CH3
HO
N
O
O
N
O
CH3NH2
CH2
HCOOH
catalysis
-H+
N
HO
O
1
2 CH3NH2
CH3
N
CH3
aromat.
NH
O
N
N
3
HCOOH(catalyst)
CH3
CH3
H3C
H3C
CH2
N
H3C
N
N
NH
HN
N
N
N
H
aromat.
-H+
Scheme 3. Reaction pathway to explain the formation of Oxazoles (3) and Imidazoles (4).
4
MgSO4 and concentrated by evaporation under reduced pressure.
The resulting residue was chromatographed on silica gel 60 (35–
70 mesh) in a (28 Â 2.5 cm) column, using a mixture CH2Cl2/EtOH
(15:1) as the eluent. The experimental physical and spectroscopical
properties of the new obtained products are summarized below.
Known product properties were coincident with the previously de-
scribed data.
(39), 77 (11). Anal. Calcd for C11H15NO: C, 74.58; H, 8.47; N, 7.91.
Found: C, 74.43; H, 8.12; N, 8.13.
N-Methyl-N-(1-(pyridine-2-yl)ethyl) formamide (2d)
Oil IR (KBr) m
/cmÀ1 = 3052, 2978, 1668, 1588, 1434, 1087, 751.
1H NMR (300 MHz; CDCl3) d (ppm): 1.62 (d, J = 7.0 Hz, 2H) (dupli-
cated signal: 1.72 (d, J = 7.0 Hz, 2H)), 2.75 (s, 3H) (duplicated sig-
nal: 2.84 (s, 3H)), 4.85 (q, J = 7.0 Hz, 1H), (duplicated signal: 5.8
(d, J = 7.0 Hz, 2H)), 7.2–7.4 (m, 2H), 7.6–7.8 (m, 1H), 8.4 (s, 1H).
8.5–8.6 (m, 1H). 13C NMR (75.4 MHz, CDCl3) d: 15.1, 17.1, 26.5,
29.7, 50.8, 58.5, 121.1, 122.4, 122.6, 122.7, 136.7, 136.8, 149.0,
149.4, 158.9, 162.6, 162.8. MS m/z (relative intensity) CI: 205
(M++41, 7), 193 (M++29, 20), 165 (M++1, 58), 137 (100), 106 (58).
Anal. Calcd for C9H12N2O: C, 65.85; H, 7.32; N, 17.08. Found: C,
66.21; H, 7.01; N, 16.79.
N-Benzyl-N-phenylformamide
Mp 44–45 °C [Lit.14 45–46 °C]. 13C NMR (75.4 MHz, CDCl3) d:
48.9, 54.2, 124.1, 126.7, 127.0, 127.5, 127.8, 128.7, 129.6, 136.6,
140.9, 159.4, 162.5. MS m/z (relative intensity) EI: 211 (M+, 80),
210 (M+À1, 21), 194 (6), 166 (9), 91 (100), 77 (7), 65 (24).
N-Cyclohexyl-N-methylformamide (2a)
Oil [Lit.22 Bp 250 °C]. IR (KBr)
m
/cmÀ1 = 2932, 2856, 1668, 1452,
N-Methyl-N-((thiophen-2-yl)methyl)formamide (2e)
1409, 1068, 895, 724. 1H NMR (300 MHz; CDCl3) d (ppm): 1.0–1.8
(m, 10H), 2.72 (s, 3H) (duplicated signal: 2.76 (s, 3H)), 3.1–3.3 (m,
1H), 8.07 (s, 1H). 13C NMR (75.4 MHz, CDCl3) d: 25.4, 25.5, 29.5,
31.3, 50.8, 58.2, 162.4. MS m/z (relative intensity) EI: 141 (M+,
60), 112 (20), 98 (90), 84 (19), 70 (83), 60 (100). IQ: 182 (M++41,
6), 170 (M++29, 20), 142 (M++1, 100), 60 (36).
Oil IR (KBr) m
/cmÀ1 = 3092, 2962, 1672, 1397, 1260, 1079, 713.
1H NMR (300 MHz; CDCl3) d (ppm): 2.58 (s, 3H) (duplicated signal:
2.65 (s, 3H)), 4.31 (s, 2H) (duplicated signal: 4.41 (s, 2H)), 6.6–6.8
(m, 2H), 6.9–7.1 (m, 1H), 7.81 (s, 1H) (duplicated signal: 8.0 (s,
1H)). 13C NMR (75.4 MHz, CDCl3) d: 29.1, 33.7, 42.1, 48.1, 125.4,
125.6, 126.3, 126.5, 126.8, 126.9, 138.0, 138.7, 161.9, 162.1. MS
m/z (relative intensity) EI: 155(M+, 50), 126 (27), 112 (19), 98
(53), 97 (100), 85 (32), 53 (21). Anal. Calcd for C7H9NOS: C,
54.19; H, 5.81; N, 9.03. Found: C, 53.82; H, 5.61; N, 9.07.
N-Methyl-N-(1-phenylethyl)formamide23 (2b)
Oil IR (KBr) m
/cmÀ1 = 3064, 2976, 1669, 1405, 1316, 1081, 913,
737. 1H NMR (300 MHz; CDCl3) d (ppm): 1.5 (d, J = 7.2 Hz, 3H)
(duplicated signal: 1.62 (d, J = 6.9 Hz, 3H)), 2.6 (s, 3H), 4.58 (q,
J = 7.2 Hz, 1H) (duplicated signal: 5.6 (q, J = 6.9 Hz, 1H), 7.2–7.4
(m, 5H), 8.1 (s, 1H) (duplicated signal: 8.35 (s, 1H)). 13C NMR
(75.4 MHz, CDCl3) d: 15.3, 17.9, 26.0, 29.5, 48.7, 56.5, 126.7,
127.3, 127.5, 127.8, 128.5, 128.7, 139.4, 139.5, 162.4, 162.6. MS
m/z (relative intensity) EI: 163 (M+, 29), 162 (M+À1, 100), 120
(20), 105 (19), 77 (18), 51 (11).
N-Benzyl-N-methylformamide (2f)
Oil [Lit.24 Bp (14 Torr) 124–126 °C]. MS m/z (relative intensity)
EI: 149 (M+, 55), 148 (M+À1, 100), 134 (12), 121 (13), 106 (39),
91 (82), 79 (64), 65 (27).
Phenanthro[9,10-d][1,3]oxazole (3g)
N-Methyl-N-(1-phenylpropyl)formamide (2c)
Mp 136–138 °C [Lit.25 137–139 °C]. MS m/z (relative intensity)
EI: 219 (M+, 100), 192 (22), 190 (25), 163 (36), 82 (5).
Oil IR (KBr) m
/cmÀ1 = 3058, 2970, 1674, 1409, 1089, 929, 763. 1H
NMR (300 MHz; CDCl3) d (ppm): 0.92 (m, 3H), 2.0 (m, 2H), 2.6 (m,
3H), 4.4 (m, 1H) (duplicated signal: 5.5 (m)), 7.1–7.3 (m, 5H), 8.1 (s,
1H) (duplicated signal: 8.3 (s)). 13C NMR (75.4 MHz, CDCl3) d: 10.7,
10.9, 21.7, 23.0, 25.5, 29.4, 54.9, 63.0, 127.0, 127.5, 127.8, 128.4,
128.6, 129.7, 138.5, 162.7, 163.0. MS m/z (relative intensity) EI:
177 (M+, 18), 176 (M+À1, 28), 148 (100), 121 (69), 107 (22), 91
1-Methylphenanthrimidazole (4g)
Mp 192–194 °C [Lit.26 196 °C]. IR (KBr)
m
/cmÀ1 = 3051, 2953,
2852, 1633, 1612, 1529, 1456, 1377, 1079, 1018, 750, 722. 1H
NMR (300 MHz; CDCl3) d (ppm): 4.25 (s, 3H), 7.5–7.7 (m, 4H),
7.82 (s, 1H), 8.3 (d, J = 9.6 Hz, 1H), 8.62 (d, J = 9.6 Hz, 2H), 8.74 (d,